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ABSTRACT
We reviewed 136 patients with advanced acute myelogenous leukemia (AML) and myelodysplastic syndrome
(MDS) undergoing allogeneic transplantation to assess the impact of conditioning regimen intensity on
outcome. Thirty-nine patients receiving nonmyeloablative stem cell transplantation (NST) were compared
with 97 patients receiving myeloablative transplantation. Patients receiving NST were at high risk for treat-
ment-related complications given that they were older, 57 vs 43 years (P < .001), and more likely had received
previous or myeloablative transplantation (54% vs 2%; P < .0001). The cumulative risk of relapse was higher
for patients after NST (61% vs 38%; P  .02). The 100-day mortality was less after NST (15% vs 32%) Overall
survival (OS) at 2 years was 28% for NST and 34% for myeloablative transplantation (P  .89). Progression-
free survival (PFS) at 2 years was 20% for NST and 31% for myeloablative transplantation (P  .31). Cox
regression analysis showed that the intensity of the conditioning regimen had no effect on either OS or PFS.
Despite the high-risk features of patients with advanced AML or MDS undergoing NST, OS and PFS in these
patients was similar to those in patients receiving myeloablative transplantation. These results demonstrate
that dose intensity plays a significant role in control of disease after transplantation, but that this benefit is
negated by increasing treatment-related mortality. These results suggest that NST is a reasonable alternative
for patients with advanced AML and MDS at high risk for complications after myeloablative transplantation.
© 2006 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
The use of nonmyeloablative conditioning be-
ore allogeneic hematopoietic stem cell transplan-
ation (HSCT) has increased dramatically over the
ast 5 years. This increase has been led in part by
he recognition that engraftment of allogeneic he-
atopoietic cells can be achieved in many cases with
ess-intensive conditioning, and that such condi-
ioning will be associated with reduced regimen-
elated toxicity. This approach has been adopted
articularly for older patients and those who have treviously undergone a fully myeloablative trans-
lantation [1-4].
The shift toward nonmyeloablative and away from
blative conditioning regimens is motivated by the
bservation that graft-versus-tumor (GVT) activity
lays a signiﬁcant role after allogeneic HSCT in some
iseases and that the antineoplastic effects of chemo-
herapy and radiation may play a secondary role. The
elative contributions of dose-intensive chemotherapy/
adiotherapy and GVT activity to the cure of patients
ikely depends on disease type and disease stage at
ransplantation.
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E. P. Alyea et al.1048Acute myelogenous leukemia (AML) and myelo-
ysplastic syndrome (MDS) are among the leading
iagnoses for which nonmyeloablative HSCT is per-
ormed. However, the role of dose intensity in pro-
ucing cures for these diagnoses is not clear, par-
icularly in patients with advanced disease. The
mportance of dose intensity for patients with AML in
rst remission was demonstrated in a randomized
tudy of high-dose versus intermediate- or low-dose
ytosine arabinoside (ara-C) as postremission intensi-
cation therapy. In patients under age 60 years, high-
ose ara-C produced superior long-term event-free
urvival and led to its routine use in ﬁrst-remission
ML patients [5].
Dose-intensive therapy has not beneﬁted all pa-
ients, however. In contrast to patients under age 60,
o improvement in outcome was observed for patients
ver age 60 receiving high-dose ara-c–based chemo-
herapy compared with less-intensive chemotherapy,
nd to date there remains no clear role for consolida-
ion chemotherapy for older individuals [6-8]. Con-
icting data also appear from studies of autologous
SCT for patients with AML. Supporting a role for
ose-intensive therapy, studies have documented
ong-term remissions and cures for patients receiving
igh-dose chemotherapy and autologous HSCT for
atients with AML beyond ﬁrst remission, whereas
tandard chemotherapy alone in these settings is al-
ost always insufﬁcient to produce cure [9,10]. In
ontrast, prospective randomized studies of autolo-
ous HSCT versus chemotherapy alone as postrem-
ssion therapy for AML in ﬁrst complete remission
ave not demonstrated a convincing advantage for
igh-dose therapy and autologous HSCT arms [11-
3]. The underlying biology of the leukemia itself has
igniﬁcant inﬂuence. The beneﬁt of high-dose therapy
as been observed in patients with favorable-risk cy-
ogenetics, but not in those with adverse karyotypic
eatures [14].
Because allogeneic HSCT using nonmyeloabla-
ive conditioning regimens depends almost entirely on
he GVL effect for success, comparing the outcome of
atients after myeloablative and nonmyeloablative
SCT may help elucidate the relative contribution of
ose-intensive conditioning to the outcome of HSCT
or patients with advanced AML or MDS. We exam-
ned our experience with nonmyeloablative transplan-
ation using low-dose intravenous busulfan and ﬂu-
arabine as conditioning in patients with advanced
ML or MDS and compared outcome and reasons for
reatment failure with those in patients with a similar
iagnosis receiving conventional high-dose prepara-
ive regimens followed by allogeneic transplantation
t our institution. The retrospective analysis included
36 patients with advanced AML or MDS receiving
ither nonmyeloablative HSCT (n  39) or myeloa-
lative HSCT (n  97). oATIENTS AND METHODS
atient Population
Patients with advanced AML or advanced MDS
eceiving unmanipulated HLA-matched allogeneic
ransplantation from 1997–2002 at our institution
ere included in the analysis. All patients had ad-
anced disease at the time of transplantation, as
eﬁned by AML beyond ﬁrst remission or MDS
ith excess blasts or secondary MDS. Eligibility
equirements for myeloablative transplantation in-
luded Eastern Cooperative Oncology Group perfor-
ance status 0–2, absence of active infection at the
ime of study entry, left ventricular ejection fraction
0%, and normal or near-normal kidney and liver
unction values. Eligibility requirements for non-
yeloablative transplantation were similar to those
or ablative transplantation, except for an ejection
raction  30%.
All patients receiving nonmyeloablative condition-
ng were evaluated for myeloablative transplantation
nd considered to have contraindications to that ap-
roach. Relative contraindications to myeloablative
ransplantation included previous myeloablative trans-
lantation, age 50 years, or signiﬁcant organ dys-
unction. Between May 2000 and December 2002, 39
atients underwent transplantation using a nonmy-
loablative approach. The decision to pursue nonmy-
loablative as opposed to myeloablative conditioning
uring this period was based on patient and physician
reference. A subset of patients over age 50 was pre-
iously reported in an analysis of outcome of elderly
atients after transplantation [3].
The Human Subjects Protection Committee of
he Dana-Farber Cancer Institute approved all inves-
igational protocols. Written informed consent was
btained in all cases.
onors
All donors included in this analysis were HLA-
atched at A, B, and DR loci. Unrelated donors were
equired to match recipients at HLA-DR loci by mo-
ecular analysis. Class II typing was performed with
equence-speciﬁc oligonucleotide probes. The major-
ty of patients (87%) in the nonmyeloablative cohort
eceived ﬁlgrastim-mobilized peripheral blood stem
ells (PBSCs). In the myeloablative group, 24 (25%)
atients received ﬁlgrastim-mobilized PBSCs and 73
75%) received bone marrow. PBSC donors in both
roups were mobilized with ﬁlgrastim at 10 g/kg/day
or 5 days. Stem cell collection was initiated on the
fth day of ﬁlgrastim administration and continued
ntil a sufﬁcient number of CD34 stem cells were
btained. The target stem cell dose was 6  106
D34 cells/kg. Bone marrow was obtained in the
perating room under general or epidural anesthesia,
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Conditioning Regimen Intensity and Transplantation Outcome 1049nd the targeted cell count was 2  108 nucleated
ells/kg.
onditioning Regimens
Patients undergoing nonmyeloablative transplan-
ation received ﬂudarabine 30 mg/m2/day on days6,
5, 4, and 3 and intravenous busulfan 0.8 mg/kg/
ay on days 6, 5, 4, and 3. The patients re-
eiving myeloablative transplantation were treated with
ither high-dose cyclophosphamide 1800 mg/m2  2
ays and fractionated total body irradiation 1400
Gy in 7 fractions over 4 days (in 91 patients [94%])
r oral busulfan 16 mg/kg divided over 4 days) and
yclophosphamide 1800 mg/m2  2 days (in 6 pa-
ients [6%]).
VHD Prophylaxis
All patients included in the analysis received im-
unosuppressive therapy as GVHD prophylaxis. The
onmyeloablative transplant recipients were treated
n sequential protocols with deﬁned GVHD prophy-
axis. Thirty patients received GVHD prophylaxis
onsisting of cyclosporine plus corticosteroids; 9 pa-
ients received tacrolimus or cyclosporine combined
ith methotrexate. Of the 97 patients who underwent
yeloablative conditioning, 91 received GVHD pro-
hylaxis consisting of tacrolimus and methotrexate or
yclosporine and methotrexate; 6 patients with a con-
raindication to methotrexate administration received
corticosteroid or rapamycin in addition to a cal-
ineurin inhibitor.
himerism Analysis
The presence of donor-derived hematopoiesis was
ssessed in the patients undergoing nonmyeloablative
ransplantation. Unfractionated donor chimerism was
ssessed from bone marrow aspirates at approximately
ay 30 and day 100 posttransplantation. Geno-
ypes of donor and recipient were determined using
NA extracted from pretransplantation samples.
ine short tandem repeat loci were typed using the
BI Proﬁler Plus Kit and ABI 310 Genetic Analyzer
Applied Biosystems, Foster City, CA) to resolve al-
eles. “Informative” alleles that were present only in
he donor or recipient were used in the chimerism
alculations. In cases of sex- mismatched donor–re-
ipient pairs for which molecular chimerism analysis
as not available, assessment of donor chimerism was
ased on ﬂuorescent in situ hybridization for X and Y
hromosomes or on cytogenetic analysis.
tatistical Considerations
Descriptive statistical analysis was performed to
ssess patient baseline characteristics, disease, disease
tatus at conditioning, GVHD prophylaxis, and source
f progenitor cells. The 2-sided Fisher’s exact test was tsed for 2  2 table analysis, and the 2-sided Wil-
oxon’s rank-sum test was used for 2-sample compar-
son of continuous variables.
Cumulative incidence curves for nonrelapse death
nd relapse with or without death were constructed
eﬂecting time to relapse and time to nonrelapse death
s competing risks. The difference between cumula-
ive incidence curves in the presence of a competing
isk was tested using the Gray method [15]. Time to
elapse and time to nonrelapse death were measured
rom the date of stem cell infusion. Patients who were
live without relapse were censored at the time last
een alive and relapse-free. Overall survival (OS) and
rogression-free survival (PFS) were calculated using
he Kaplan-Meier method. The log-rank test was used
or comparisons of Kaplan-Meier curves. PFS was
eﬁned as the time from stem cell infusion to relapse
r death from any cause. OS was deﬁned as the time
rom stem cell infusion to death from any cause. Po-
ential prognostic factors for OS, PFS, relapse, and
onrelapse death were examined using the propor-
ional hazards model and the competing-risks re-
ression model. The competing-risks regression
odel is a semiparametric proportional hazards
odel for subdistribution of relapse (or nonrelapse
eath) in the presence of a competing risk [16]. All
nteraction terms, including interaction with time,
ere examined in the proportional hazards regres-
ion model.
ESULTS
atient Characteristics
The characteristics of all patients are detailed in
able 1. AML was present in 59% of the recipients of
onmyeloablative conditioning and in 61% of the
ecipients of myeloablative conditioning, with the re-
ainder in each group having MDS. Active disease
as present at the time of transplantation in 83% of
he patients with AML receiving nonmyeloablative
ransplantation and in 68% of the patients with AML
eceiving myeloablative transplantation. All patients
eceived unmanipulated marrow or PBSCs with im-
unosuppressive medication as GVHD prophylaxis.
he patients receiving nonmyeloablative transplanta-
ion were signiﬁcantly older than those receiving my-
loablative transplantation (median age, 56 years
range, 21–70 years] vs 43 [21–65], respectively; P 
0001); 26% of those receiving nonmyeloablative
ransplantation were over age 60, compared with only
% of myeloablative transplantation recipients (P 
0002). Patients receiving nonmyeloablative condi-
ioning were more likely to have had previous myeloa-
lative transplantation (54% vs 2%; P  .0001). The
onor source was similar in both groups, with 59% of
hose receiving nonmyeloablative conditioning and
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E. P. Alyea et al.10503% of those receiving myeloablative conditioning
aving unrelated donors (P  .13). The primary indi-
ations for patients receiving nonmyeloablative trans-
lantation are outlined in Table 2. The median fol-
ow-up for those still alive is 35 months (range, 16–49
onths) for patients receiving nonmyeloablative
ransplantation and 40 months (range, 21–82 months)
or those receiving myeloablative transplantation.
VHD and Treatment-Related Mortality
The incidence of grade 2–4 acute GVHD was
imilar in patients receiving nonmyeloablative trans-
lantation and those receiving myeloablative trans-
lantation: 26% and 27%, respectively (Table 3). The
ncidence of extensive chronic GVHD was increased
n patients receiving nonmyeloablative transplantation
33%) compared with those receiving myeloablative
ransplantation (18%) (P  .04).
able 1. Patient Characteristics
Nonmyeloa
39
ge (years) 56 (21–
>50 24 (62%
>60 10 (26%
isease type
AML 23 (59%
Second complete remission 4 (17%
Relapse 19 (83%
Induction —
Failure/untreated
MDS 16 (41%
RA/RARS 5 (31%
RAEB/CMML 11 (69%
ype of transplant
MRD 16 (41%
URD 23 (59%
ransplant conditioning regimen
Flu/Bu 39 (100
CTX/TBI 0
Bu/CTX 0
VHD prophylaxis
Cyclosporine/prednisone 30
Tacrolimus or Cyclo/MTX 9
tem cell source
PBSC 34 (87%
BM 5 (13%
revious myeloablative
transplantation 21 (54%
A, refractory anemia; RARS, refractory anemia with ringed sid
elomonocytic leukemia; MRD, matched related donor; URD, u
TBI, total body irradiation; MTX, methotrexate; BM, bone ma
able 2. Primary Indications for Nonmyeloablative Transplantation
Indication n (%)
dvanced age (>50 yrs) 13 (33%)
revious myeloablative transplantation 21 (54%)
ther medical condition/organ dysfunction 5 (13%)Day 100 mortality was lower for patients receiving
onmyeloablative conditioning than for recipients of
yeloablative conditioning (15% vs 32%). Despite
he difference in 100-day mortality, the cumulative
ncidence of nonrelapse mortality was similar: 26% for
atients receiving nonmyeloablative conditioning,
ompared with 33% for those receiving myeloablative
onditioning (P  .28) (Figure 1). Nonrelapse death
nd relapse were considered competing risks in this
nalysis. The major causes of nonrelapse mortality for
atients receiving nonmyeloablative transplantation
ere GVHD and infection (Table 4).
elapse
Disease relapse was the primary cause of treatment
ailure in patients receiving nonmyeloablative trans-
lantation. The cumulative incidence of relapse in the
Myeloablative P
97
43 (21–65) <.0001
26 (27%) .0001
3 (3%) .0002
59 (61%) .85
14 (17%)
19 (32%)
21 (36%)
38 (39%)
1 (3%)
37 (97%)
.13
55 (57%)
42 (43%)
0
91 (94%)
6 (6%)
6
91
<.0001
24 (25%)
73 (75%)
2 (2%) <.0001
ts; RAEB, refractory anemia excess blasts; CMML, chronic my-
d donor; Flu, ﬂudarabine; Bu, busulfan; CTX, cyclophosphamide;
able 3. Incidence of Acute GVHD
Grade of GVHD Nonmyeloablative Myeloablative
0 26 (67%) 46 (47%)
1 3 (8%) 25 (26%)
2 2 (5%) 13 (13%)blative
70)
)
)
)
)
)
)
)
)
)
)
%)
)
)
)
eroblas
nrelate3–4 8 (21%) 13 (13%)
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Conditioning Regimen Intensity and Transplantation Outcome 1051resence of treatment-related mortality (TRM) as a
ompeting risk was 61% for patients receiving non-
yeloablative conditioning and 38% for those receiv-
ng myeloablative conditioning (P  .02) (Figure 1).
owever, this difference was no longer signiﬁcant at
he 0.05 level when other prognostic factors were
djusted in a competing-risks regression analysis (P 
06; data not shown).
S and PFS
Despite the adverse characteristics of the patients
eceiving NST, no difference in OS or PFS was seen
n patients receiving nonmyeloablative or myeloabla-
ive HSCT. Estimated OS at 2 years was 28% for
onmyeloablative transplantation recipients and 34%
or myeloablative transplantation recipients (P  .89)
Figure 2; Table 5). Estimated PFS at 2 years was 20%
or nonmyeloablative transplantation recipients and
1% for myeloablative transplantation recipients (P 
31) (Figure 3; Table 5).
Cox regression analysis was performed to identify
he factors associated with OS and PFS for all patients.
actors analyzed included age, transplantation condi-
ioning regimen (nonmyeloablative vs myeloablative),
atient–donor sex mismatch, donor type (related vs
nrelated), stem cell source (bone marrow vs periph-
ral blood), and previous transplantation. No factors,
ncluding the intensity of the conditioning regimen,
able 4. Causes of Treatment Failure
Nonmyeloablative Myeloablative
VHD 4 (13%) 3 (5%)
nfection 4 (13%) 4 (6%)
OD 0 5 (8%)
ther 1 (3%) 6 (9%)
ulmonary 1 (3%) 14 (21%)
elapse 20 (67%) 35 (52%)
igure 1. Cumulative incidence of TRM (P  .28) and risk of rela
atients with advanced AML or MDS.TOD, veno-occlusive disease.nﬂuenced either OS or PFS. In a subset analysis of
atients over age 50 years, estimated OS at 2 years was
5% for nonmyeloablative transplantation recipients
nd 12% for myeloablative transplantation recipients
P  .06), and estimated PFS at 2 years was 13% and
2%, respectively, for these 2 groups (P  .31).
For patients for whom cytogenetic data were avail-
ble (n  100), as expected, patients with favorable or
ntermediate-risk cytogenetics had a better 2-year OS
nd PFS than those with unfavorable cytogenetics
OS, 43% favorable/intermediate vs 18% unfavorable,
 .02; PFS, 41% favorable/intermediate vs 13%
nfavorable, P  .006). The intensity of the condi-
ioning regimen did not inﬂuence outcome for pa-
ients with favorable/intermediate risk cytogenetics
OS, 46% NST vs 42% myeloablative, P  .87; PFS,
8% NST vs 42% myeloablative, P  .64). Similarly,
he intensity of the conditioning regimen did not
nﬂuence outcome for patients with unfavorable cyto-
enetics (OS, NST 20% vs myeloablative 17%, P 
45; PFS, 7% NST vs 17% myeloablative, P  .89).
ffect of Early Donor Chimerism on Outcome
fter Nonmyeloablative Transplantation
Hematopoietic chimerism was assessed at approx-
mately 1 month after nonmyeloablative transplanta-
ion. Thirty-four of 39 patients had samples available
or analysis and could be evaluated. The median do-
or-derived chimerism was 92% (range, 0–100%).
atients with donor chimerism 90% at 1 month had
signiﬁcantly improved OS at 1 year (72% vs 31%)
nd 2 years (44% vs 19%) compared with those with
onor chimerism 90% (P  .02). Similarly, patients
ith 90% donor-derived hematopoiesis had an im-
roved PFS at 1 year (44% vs 19%) and 2 years (33%
nd 13%) compared with those with 90% donor-
erived hematopoiesis, although this difference did
ot reach statistical signiﬁcance (P  .10) (Figure 4).
 .02) after nonmyeloablative or myeloablative transplantation forpse (Phere was no association between the degree of donor
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E. P. Alyea et al.1052himerism achieved early after transplantation and the
evelopment of acute GVHD or TRM.
ISCUSSION
This retrospective comparison of patients with
dvanced AML and MDS receiving either a nonmy-
loablative or a myeloablative conditioning regimen
efore allogeneic HSCT suggests that the less toxic
udarabine/intravenous busulfan–based nonmyeloab-
ative regimen produces results similar to those of the
yeloablative conditioning regimen. Although retro-
pective analysis such as this are open to criticism
egarding the comparability of patients in each cohort,
he patients in the nonmyeloablative group were a
igher-risk population by virtue of being older and
ere more likely to be undergoing their second trans-
lantation procedure. Therefore, the ﬁnding that
onmyeloablative conditioning with ﬂudarabine/low-
ose busulfan was associated with comparable OS and
FS with a conventional myeloablative regimen is
orthy of attention.
The results demonstrate that there is a moderate
VL effect mediated after nonmyeloablative trans-
lantation in patients with advanced AML or MDS,
esulting in a 20% PFS at 2 years after transplan-
ation. The relapse rate after nonmyeloablative
able 5. OS and PFS
Median (95% CI)
(Months)
2
Years
3
Years P
S
Nonmyeloablative 9.1 (6–16) 28% 22% .89
Myeloablative 6.7 (5–15) 34% 33%
FS
Nonmyeloablative 5.6 (4–7) 20% 13% .31
Figure 2. OS in patients receiving nonmyeloablative transplanG
Myeloablative 5.7 (4–12) 31% 29%ransplantation is high compared with that after my-
loablative transplantation, suggesting that dose in-
ensity contributes to improved disease control. With
espect to patients over age 50, dose intensity appears
o play a minimal role, with an essentially identical
FS seen in both groups. An European Bone Marrow
ransplantation Group retrospective comparison of
onmyeloablative and myeloablative transplantation
f patients over age 50 with AML reached a similar
onclusion, with similar leukemia-free survival be-
ween the 2 approaches [17]. De Lima et al [15]
ompared regimens of different dose intensities in
atients with AML. They evaluated the moderately
ntensive ﬂudarabine/cytosine arabinoside/idarubicin
nd the more highly intensive ﬂudarabine/melphalan.
lthough the difference in intensity in that compari-
on was not as marked as in our ﬂuarabine/low-dose
ntravenous busulfan versus cyclophosphamide/total
ody irradiation, they reported superior survival in the
ore intensive ﬂudarabine/melphalan group, but only
n patients who were in complete remission at the time
f transplantation. Another retrospective analysis fo-
using on patients with MDS or AML with multilin-
age dysplasia demonstrated similar OS and PFS for
atients receiving either nonmyeloablative or myeloa-
lative transplantation [18].
The lack of signiﬁcant beneﬁt from high-dose
hemotherapy is not surprising, especially in older
atients with advanced disease. The leukemia in older
ndividuals is relatively resistant to chemotherapy,
ith lower initial complete remission rates, and these
atients are not cured using standard chemotherapy
egimens [19]. Similarly, patients with relapsed AML
re relatively chemotherapy resistant, as demonstrated
y a low rate of complete response to salvage chemo-
herapy and a short duration of response. It is likely
hat both of these patient populations rely largely on
nd patients receiving myeloablative transplantation (P  .89).VL effects for long-term responses. In these pa-
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Conditioning Regimen Intensity and Transplantation Outcome 1053ients, the conditioning regimen still plays an impor-
ant role, perhaps not for its antineoplastic effects, but
ather for its ability to induce lymphohematopoietic
onor chimerism or to achieve sufﬁcient cytoreduc-
ion, thereby controlling the disease long enough to
llow the GVL response to develop.
Longer follow-up could reveal that myeloablative
ransplantation may be associated with improved PFS,
lthough most relapses for patients with advanced
ML or MDS occur within the ﬁrst 2 years of trans-
lantation. Dose-intensive chemotherapy and radia-
ion certainly contribute directly to cure in some pa-
ients; however, increased treatment-related toxicity is
lso noted. This trade-off between increased risk of
elapse and lower TRM associated with nonmyeloab-
ative transplantation has been noted in other studies
omparing outcome in patients receiving nonmyeloa-
lative transplantation and those receiving myeloab-
Figure 3. PFS in patients receiving nonmyeloablative transplan
igure 4. OS for patients with AML or MDS after nonmyeloabl
ematopoiesis with patients with 90% donor-derived hematopoiesis 1 mative transplantation. Consequently, for the individ-
al patient, careful consideration of the potential
eneﬁts of dose intensity must be counterbalanced by
he patient’s risk for transplantation-related complica-
ions. Comorbidity indices, which assess the impact of
ther medical conditions, may help quantify a pa-
ient’s risk of transplantation-related complications
nd allow for a better estimate of the risk associated
ith myeloablative transplantation [20,21]. If signiﬁ-
ant risk factors for TRM from dose-intensive therapy
re not present, then myeloablative transplantation
ay be preferred. However, our data suggest that
ose-intensive therapy is of no beneﬁt in patients over
ge 50 with advanced AML or MDS. Keep in mind,
owever, that our results shed no light on the role of
onmyeloablative transplantation for patients in ﬁrst
emission or early-stage MDS, in whom dose-inten-
ive chemotherapy/radiotherapy may be important.
and patients receiving myeloablative transplantation (P  .31).
ansplantation comparing patients achieving 90% donor-derivedative tr
onth after transplantation (P  .02).
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E. P. Alyea et al.1054In the current study, patients who achieved90%
onor-derived hematopoiesis early after nonmyeloab-
ative transplantation had better OS than those who
chieved 90% donor-derived hematopoiesis. An-
ther study by Baron et al [22] demonstrated that
atients achieving full T-cell donor chimerism after
onmyeloablative transplantation had a decreased risk
f progression or relapse [22]. That study demon-
trated that donor chimerism had the greatest impact
n outcome in patients with AML, MDS, and myelo-
roliferative disorders. These ﬁndings may indicate
hat perhaps achieving a high degree of donor-derived
himerism after nonmyeloablative transplantation is a
urrogate marker for the GVL effect, and that the
VL effect is not leukemia-speciﬁc but rather is di-
ected against hematopoietic antigens that are shared
ith hematopoietic stem cells and progenitors. If this
upposition is correct, then attempting to achieve
igher degrees of donor chimerism by administering
ore-intensive chemotherapy may not lead to im-
roved outcome. In the current study, multivariate
nalysis did not identify any speciﬁc factor (including
onor–recipient sex mismatch, development of acute
VHD, or number of CD34 cells infused) that in-
uenced chimerism after transplantation. It is not
lear whether attempting to enhance donor chimerism
or patients with a low degree of donor chimerism by
mmunologic manipulation, such as prophylactic do-
or lymphocyte infusion, will inﬂuence outcome.
Our current challenge is to determine how to best
ugment these GVL effects without inducing dis-
bling acute or chronic GVHD, conditions account-
ng for much of the morbidity and mortality of non-
yeloablative HSCT. It would be ideal if we could
enerate speciﬁc immune responses independently of
VHD, perhaps through the development and ad-
inistration of whole cell or peptide vaccines [23,24].
t this juncture, it remains unclear what level of dose
ntensity should be used in conditioning regimens for
atients with AML or MDS. For now, our data sug-
est that it is reasonable to treat patients with ad-
anced AML or MDS with conditioning regimens
hat are less toxic but still sufﬁciently potent to pro-
ote donor lymphohematopoietic engraftment. Given
hat dose intensity may be important in some patients,
yeloablative transplantation may be preferred unless
igniﬁcant risk factors for treatment-related compli-
ations are present.
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